EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

Danilo Menichelli iD, Gianluca Gazzaniga, Emilia Antonucci, Gualtiero Palareti, Daniela Poli iD, Pasquale Pignatelli, Daniele Pastori iD, START2 Register Investigators

European Journal of Clinical Investigation · 2026

DOI: 10.1111/eci.70148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Danilo Menichelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Surgical Specialty and Anesthesiology Paride Stefanini, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Obesity, Overweight, Anticoagulants. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Overweight and obesity are highly prevalent in atrial fibrillation (AF) patients, yet the best anticoagulant strategy for this group is still unclear. We evaluated the risk of all‐cause mortality and cardiovascular events (CVEs) in overweight and obese AF patients treated with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs).

Methods

We analysed 10,259 AF patients on anticoagulants from the prospective nationwide START registry. Overweight was defined as BMI 25–29.9 kg/m 2 and obesity as BMI ≥30 kg/m 2 . Mortality risk was assessed with Cox proportional hazards models, and CVEs with Fine–Grey models accounting for competing risks. Additional modelling strategies, subgroup analyses, and propensity score matching were performed to explore data and ensure robustness.

Results

Overall, 6534 (63.7%) patients had BMI >25 kg/m 2 (65.7% overweight, 34.3% obese). Over a median follow‐up of 17.4 months, 408 deaths and 481 CVEs occurred. DOACs' use was associated with a lower risk of all‐cause mortality (HR 0.57, 95% CI 0.46–0.70, p < 0.001) and CVEs (sHR 0.71, 95% CI 0.59–0.86, p < 0.001) versus VKAs. The inverse association of DOACs with mortality was evident in both overweight (HR 0.52, 95% CI 0.39–0.68, p < 0.001) and obese patients (HR 0.69, 95% CI 0.48–0.98, p = 0.040), while the reduction in CVEs reached significance only in the overweight group.

Conclusions

In this nationwide registry, DOACs were associated with lower risks of mortality and CVEs compared with VKAs across BMI groups, though the CVE effect was not evident in obese patients. These findings suggest a potential mortality advantage of DOACs irrespective of BMI, warranting further confirmation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationObesityOverweightAnticoagulantsCardiovascular DiseasesFactor Xa InhibitorsHumansMaleFemaleAgedRegistriesAged, 80 and overVitamin KMiddle AgedAdministration, OralProportional Hazards ModelsCause of DeathBody Mass IndexStrokeProspective StudiesRivaroxabanPyrazoles

Stichwörter der Autor:innen

BMIDOACVKAatrial fibrillationobesityoverweight

Substanzen

AnticoagulantsVitamin KFactor Xa InhibitorsRivaroxabanPyrazoles

Autor:innen und Institutionen

  • Department of General Surgery, Surgical Specialty and Anesthesiology Paride Stefanini, Sapienza University of Rome, Rome, Italy.
  • Arianna Anticoagulazione Foundation, Bologna, Italy.
  • Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy.
  • Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • IRCCS Neuromed, Località Camerelle, Pozzilli, Isernia, Italy.

ORCID-Profile: Danilo Menichelli, Daniela Poli, Daniele Pastori

Zitieren

APA

Menichelli, D., Gazzaniga, G., Antonucci, E., Palareti, G., Poli, D., Pignatelli, P., Pastori, D., & START2 Register Investigators (2026). Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70148

Vancouver

Menichelli D, Gazzaniga G, Antonucci E, Palareti G, Poli D, Pignatelli P, et al. Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70148

BibTeX
@article{Menichelli2026,
  author = {Menichelli, Danilo and Gazzaniga, Gianluca and Antonucci, Emilia and Palareti, Gualtiero and Poli, Daniela and Pignatelli, Pasquale and Pastori, Daniele and START2 Register Investigators, START2 Register Investigators},
  title = {Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1111/eci.70148}
}
Kostenlos starten →